Virax Biolabs Group Statistics
Total Valuation
VRAX has a market cap or net worth of $8.73 million. The enterprise value is $1.82 million.
Important Dates
The next estimated earnings date is Tuesday, December 3, 2024, before market open.
| Earnings Date | Dec 3, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
VRAX has 4.34 million shares outstanding. The number of shares has increased by 50.43% in one year.
| Current Share Class | 4.34M |
| Shares Outstanding | 4.34M |
| Shares Change (YoY) | +50.43% |
| Shares Change (QoQ) | +26.04% |
| Owned by Insiders (%) | 6.63% |
| Owned by Institutions (%) | 5.04% |
| Float | 4.05M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 63.25 |
| Forward PS | n/a |
| PB Ratio | 0.60 |
| P/TBV Ratio | 1.01 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 21.40 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.58, with a Debt / Equity ratio of 0.07.
| Current Ratio | 11.58 |
| Quick Ratio | 10.54 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -148.24 |
Financial Efficiency
Return on equity (ROE) is -90.63% and return on invested capital (ROIC) is -51.27%.
| Return on Equity (ROE) | -90.63% |
| Return on Assets (ROA) | -47.66% |
| Return on Capital (ROIC) | -51.27% |
| Revenue Per Employee | $4,992 |
| Profits Per Employee | -$387,077 |
| Employee Count | 17 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 0.42 |
Taxes
| Income Tax | -136,661 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -13.73% in the last 52 weeks. The beta is 1.92, so VRAX's price volatility has been higher than the market average.
| Beta (5Y) | 1.92 |
| 52-Week Price Change | -13.73% |
| 50-Day Moving Average | 2.02 |
| 200-Day Moving Average | 1.57 |
| Relative Strength Index (RSI) | 49.78 |
| Average Volume (20 Days) | 272,246 |
Short Selling Information
The latest short interest is 446,542, so 10.28% of the outstanding shares have been sold short.
| Short Interest | 446,542 |
| Short Previous Month | 231,828 |
| Short % of Shares Out | 10.28% |
| Short % of Float | 11.01% |
| Short Ratio (days to cover) | 0.11 |
Income Statement
In the last 12 months, VRAX had revenue of $84,872 and -$6.58 million in losses. Loss per share was -$2.47.
| Revenue | 84,872 |
| Gross Profit | 33,598 |
| Operating Income | -6.28M |
| Pretax Income | -6.92M |
| Net Income | -6.58M |
| EBITDA | -6.11M |
| EBIT | -6.28M |
| Loss Per Share | -$2.47 |
Full Income StatementBalance Sheet
The company has $7.29 million in cash and $603,202 in debt, giving a net cash position of $6.68 million or $1.54 per share.
| Cash & Cash Equivalents | 7.29M |
| Total Debt | 603,202 |
| Net Cash | 6.68M |
| Net Cash Per Share | $1.54 |
| Equity (Book Value) | 8.42M |
| Book Value Per Share | 3.36 |
| Working Capital | 7.34M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$4.57 million and capital expenditures -$707,916, giving a free cash flow of -$5.28 million.
| Operating Cash Flow | -4.57M |
| Capital Expenditures | -707,916 |
| Free Cash Flow | -5.28M |
| FCF Per Share | -$1.22 |
Full Cash Flow StatementMargins
| Gross Margin | 39.59% |
| Operating Margin | -7,397.95% |
| Pretax Margin | -7,915.62% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -7,628.04% |